Vytorin Captures 2% Of New Prescriptions In Cholesterol Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.